Investing.com - Precigen (NASDAQ: PGEN) reported first quarter EPS of $-0.390, $0.31 worse than the analyst estimate of $-0.080. Revenue for the quarter came in at $6.23M versus the consensus estimate of $1.64M.
Precigen's stock price closed at $1.440. It is up 14.290% in the last 3 months and up 41.180% in the last 12 months.
Precigen saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Precigen's stock price’s past reactions to earnings here.
According to InvestingPro, Precigen's Financial Health score is "fair performance".
Check out Precigen's recent earnings performance, and Precigen's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
Should you invest $2,000 in PGEN right now?
With PGEN making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed PGEN alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including PGEN, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is PGEN poised for similar growth? Don't miss the opportunity to find out.
Reveal Undervalued Stocks Now